1.28
Milestone Pharmaceuticals Inc stock is traded at $1.28, with a volume of 1.43M.
It is up +1.59% in the last 24 hours and down -31.91% over the past month.
Milestone Pharmaceuticals Inc is a biopharmaceutical company dedicated to developing and commercializing etripamil for the treatment of cardiovascular medicines. Etripamil is a calcium channel blocker developed as a rapid-onset nasal spray to be administered by the patient to treat episodes of paroxysmal supraventricular tachycardia, or PSVT. The company has an ongoing Phase 2 clinical trial for patients with atrial fibrillation experiencing a rapid ventricular rate (AFib-RVR).
See More
Previous Close:
$1.26
Open:
$1.28
24h Volume:
1.43M
Relative Volume:
0.61
Market Cap:
$53.89M
Revenue:
-
Net Income/Loss:
$-59.69M
P/E Ratio:
-0.9209
EPS:
-1.39
Net Cash Flow:
$-46.54M
1W Performance:
+44.00%
1M Performance:
-31.91%
6M Performance:
-11.11%
1Y Performance:
-18.99%
Milestone Pharmaceuticals Inc Stock (MIST) Company Profile
Name
Milestone Pharmaceuticals Inc
Sector
Industry
Phone
(514) 336-0444
Address
1111 BOUL. DR.-FREDERIK-PHILIPS, STE 420, MONTREAL, QC
Compare MIST with other stocks
Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
---|---|---|---|---|---|---|
![]()
MIST
Milestone Pharmaceuticals Inc
|
1.28 | 53.89M | 0 | -59.69M | -46.54M | -1.39 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
493.84 | 122.76B | 11.02B | -535.60M | -978.00M | -2.20 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
602.64 | 61.38B | 14.20B | 4.41B | 3.54B | 38.28 |
![]()
ARGX
Argen X Se Adr
|
614.76 | 36.37B | 2.19B | 833.04M | -1.28B | 12.71 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
251.56 | 30.12B | 2.25B | -278.16M | -42.59M | -2.17 |
![]()
ONC
Beigene Ltd Adr
|
244.90 | 24.70B | 3.81B | -644.79M | -669.77M | -6.24 |
Milestone Pharmaceuticals Inc Stock (MIST) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Aug-22-24 | Initiated | Rodman & Renshaw | Buy |
Jun-20-23 | Downgrade | Jefferies | Buy → Hold |
Apr-22-22 | Upgrade | Piper Sandler | Neutral → Overweight |
Mar-05-21 | Initiated | H.C. Wainwright | Buy |
Jul-29-20 | Upgrade | Oppenheimer | Perform → Outperform |
Jul-24-20 | Upgrade | Jefferies | Hold → Buy |
Mar-25-20 | Downgrade | Jefferies | Buy → Hold |
Mar-24-20 | Downgrade | Oppenheimer | Outperform → Perform |
Mar-24-20 | Downgrade | Piper Sandler | Overweight → Neutral |
Jun-04-19 | Initiated | Oppenheimer | Outperform |
Jun-03-19 | Initiated | Cowen | Outperform |
Jun-03-19 | Initiated | Jefferies | Buy |
Jun-03-19 | Initiated | Piper Jaffray | Overweight |
View All
Milestone Pharmaceuticals Inc Stock (MIST) Latest News
Milestone Pharmaceuticals Inc (MIST) looking to reclaim success with recent performance - Sete News
Market Watch Highlights: Milestone Pharmaceuticals Inc (MIST) Ends on an Upturn Note at 1.06 - DWinneX
Milestone Pharmaceuticals Inc’s Mixed Bag: Down -30.82% in 6 Months, Down -48.21% in 30 Days - investchronicle.com
A stock that deserves closer examination: Milestone Pharmaceuticals Inc (MIST) - uspostnews.com
Milestone Pharmaceuticals Inc [MIST] Investment Guide: What You Need to Know - knoxdaily.com
Milestone Pharmaceuticals: A Golden Opportunity To Buy On Etripamil's CRL In PSVT - Seeking Alpha
Research Analysts Set Expectations for MIST Q1 Earnings - Defense World
MIST stock touches 52-week low at $0.7 amid market challenges - Investing.com Canada
MIST Stock Falls 66% Following Complete Response Letter for Cardamyst - MSN
MIST stock touches 52-week low at $0.7 amid market challenges By Investing.com - Investing.com South Africa
Milestone Pharmaceuticals (NASDAQ:MIST) Cut to Hold at TD Cowen - Defense World
Milestone Pharmaceuticals downgraded to Hold from Buy at TD Cowen - Yahoo Finance
Milestone Pharmaceuticals (NASDAQ:MIST) Downgraded by TD Securities to Hold - Defense World
TD downgrades Milestone Pharmaceuticals, suspends target on Etripamil uncertainty By Investing.com - Investing.com South Africa
HC Wainwright Adjusts Price Target on Milestone Pharmaceuticals to $10 From $25, Maintains Buy Rating - MarketScreener
Milestone Pharmaceuticals price target lowered to $10 from $25 at H.C. Wainwright - TipRanks
TD Cowen Downgrades Milestone Pharmaceuticals to Hold From Buy - MarketScreener
Milestone Pharmaceuticals stock rating cut to hold by TD Cowen - Investing.com India
Milestone Pharmaceuticals Stock Plunges 60% After FDA Declines To Approve Its Cardamyst Nasal Spray – But Reta - Asianet Newsable
HC Wainwright Reaffirms “Buy” Rating for Milestone Pharmaceuticals (NASDAQ:MIST) - Defense World
Milestone CRL affirms integrity of clinical data, says H.C. Wainwright - Yahoo Finance
Milestone Pharmaceuticals Stock Plunges 60% After FDA Declines To Approve Its Cardamyst Nasal Spray – But Retail’s Positive - NewsBreak: Local News & Alerts
Sector Update: Health Care Stocks Mixed Friday Afternoon - TradingView
Sector Update: Health Care - TradingView
US FDA declines to approve Milestone's heart rhythm nasal spray; shares halve - Reuters
Milestone Pharmaceuticals: Buy Rating Affirmed Despite CARDAMYST Approval Delay, Strong Market Potential and Robust Financial Position - TipRanks
Milestone Pharmaceuticals (MIST) Receives FDA Response on Etripa - GuruFocus
Milestone flagging following CRL - The Pharma Letter
Piper Sandler Adjusts Price Target on Milestone Pharmaceuticals to $4 From $5, Maintains Overweight Rating - Marketscreener.com
Milestone Pharma says FDA declined to approve heart disorder therapy - MSN
Milestone Pharmaceuticals Says FDA Cites Manufacturing Concerns for Etripamil NDA; Shares Fall - Marketscreener.com
FDA Declines Milestone Pharmaceuticals' (MIST) Heart Drug Approval - GuruFocus
Manufacturing issues trip up Milestone's long-awaited FDA landmark - FiercePharma
Milestone Pharma stock in focus after FDA snub (MIST:NASDAQ) - Seeking Alpha
FDA flags issues with Milestone’s new drug application By Investing.com - Investing.com South Africa
FDA Issues Complete Response Letter For Etripamil For PSVT - Marketscreener.com
Milestone Pharma slumps after FDA declines to approve heart rhythm nasal spray - TradingView
FDA flags issues with Milestone’s new drug application - Investing.com India
Milestone Pharmaceuticals announces FDA issued CRL for etripamil - TipRanks
US FDA declines to approve Milestone's heart rhythm nasal spray - MarketScreener
FDA Issues Complete Response Letter for Etripamil for PSVT - The Manila Times
US FDA declines to approve Milestone Pharma's heart rhythm nasal spray - Marketscreener.com
Milestone Pharmaceuticals Inc. Announces FDA Issues Complete Response Letter for Etripamil for PSVT - MarketScreener
Pre-market Movers: RGLS, SLNO, OCEA, OSRH... - RTTNews
Milestone Pharmaceuticals Inc Stock (MIST) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):